1
|
Strell C, Rodríguez-Tomàs E, Östman A. Functional and clinical roles of stromal PDGF receptors in tumor biology. Cancer Metastasis Rev 2024:10.1007/s10555-024-10194-7. [PMID: 38980580 DOI: 10.1007/s10555-024-10194-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 06/12/2024] [Indexed: 07/10/2024]
Abstract
PDGF receptors play pivotal roles in both developmental and physiological processes through the regulation of mesenchymal cells involved in paracrine instructive interactions with epithelial or endothelial cells. Tumor biology studies, alongside analyses of patient tissue samples, provide strong indications that the PDGF signaling pathways are also critical in various types of human cancer. This review summarizes experimental findings and correlative studies, which have explored the biological mechanisms and clinical relevance of PDGFRs in mesenchymal cells of the tumor microenvironment. Collectively, these studies support the overall concept that the PDGF system is a critical regulator of tumor growth, metastasis, and drug efficacy, suggesting yet unexploited targeting opportunities. The inter-patient variability in stromal PDGFR expression, as being linked to prognosis and treatment responses, not only indicates the need for stratified approaches in upcoming therapeutic investigations but also implies the potential for the development of PDGFRs as biomarkers of clinical utility, interestingly also in settings outside PDGFR-directed treatments.
Collapse
Affiliation(s)
- Carina Strell
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Bergen University, Bergen, Norway
| | | | - Arne Östman
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Bergen University, Bergen, Norway.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
2
|
Ai JY, Liu CF, Zhang W, Rao GW. Current status of drugs targeting PDGF/PDGFR. Drug Discov Today 2024; 29:103989. [PMID: 38663580 DOI: 10.1016/j.drudis.2024.103989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 04/02/2024] [Accepted: 04/17/2024] [Indexed: 04/30/2024]
Abstract
As an important proangiogenic factor, platelet-derived growth factor (PDGF) and its receptor PDGFR are highly expressed in a variety of tumors, fibrosis, cardiovascular and neurodegenerative diseases. Targeting the PDGF/PDGFR pathway is therefore a promising therapeutic strategy. At present, a variety of PDGF/PDGFR targeted drugs with potential therapeutic effects have been developed, mainly including PDGF agonists, inhibitors targeting PDGFR and proteolysis targeting chimera (PROTACs). This review clarifies the structure, biological function and disease correlation of PDGF and PDGFR, and it discusses the current status of PDGFR-targeted drugs, so as to provide a reference for subsequent research.
Collapse
Affiliation(s)
- Jing-Yan Ai
- College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, PR China
| | - Chen-Fu Liu
- School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, PR China
| | - Wen Zhang
- College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, PR China
| | - Guo-Wu Rao
- College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, PR China.
| |
Collapse
|
3
|
Gamradt P, Thierry K, Masmoudi M, Wu Z, Hernandez-Vargas H, Bachy S, Antonio T, Savas B, Hussain Z, Tomasini R, Milani P, Bertolino P, Hennino A. Stiffness-induced cancer-associated fibroblasts are responsible for immunosuppression in a platelet-derived growth factor ligand-dependent manner. PNAS NEXUS 2023; 2:pgad405. [PMID: 38111825 PMCID: PMC10727001 DOI: 10.1093/pnasnexus/pgad405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 11/02/2023] [Indexed: 12/20/2023]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is associated with a vast stromal reaction that arises mainly from cancer-associated fibroblasts (CAFs) and promotes both immune escape and tumor growth. Here, we used a mouse model with deletion of the activin A receptor ALK4 in the context of the KrasG12D mutation, which strongly drives collagen deposition that leads to tissue stiffness. By ligand-receptor analysis of single-cell RNA-sequencing data, we identified that, in stiff conditions, neoplastic ductal cells instructed CAFs through sustained platelet-derived growth factor (PDGF) signaling. Tumor-associated tissue rigidity resulted in the emergence of stiffness-induced CAFs (siCAFs) in vitro and in vivo. Similar results were confirmed in human data. siCAFs were able to strongly inhibit CD8+ T-cell responses in vitro and in vivo, promoting local immunosuppression. More importantly, targeting PDGF signaling led to diminished siCAF and reduced tumor growth. Our data show for the first time that early paracrine signaling leads to profound changes in tissue mechanics, impacting immune responses and tumor progression. Our study highlights that PDGF ligand neutralization can normalize the tissue architecture independent of the genetic background, indicating that finely tuned stromal therapy may open new therapeutic avenues in pancreatic cancer.
Collapse
Affiliation(s)
- Pia Gamradt
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
| | - Kevin Thierry
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
| | - Melissa Masmoudi
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
- StromaCare, Lyon F-69008, France
| | - Zhichong Wu
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
- Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Hector Hernandez-Vargas
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
| | - Sophie Bachy
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
- StromaCare, Lyon F-69008, France
| | - Tiffanie Antonio
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
| | - Berkan Savas
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
| | | | | | | | - Philippe Bertolino
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
| | - Ana Hennino
- Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
- Université Lyon 1, Lyon F-69000, France
- Centre Léon Bérard, Lyon F-69008, France
- StromaCare, Lyon F-69008, France
| |
Collapse
|
4
|
Haraya K, Tsutsui H, Komori Y, Tachibana T. Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. Pharmaceuticals (Basel) 2022; 15:ph15050508. [PMID: 35631335 PMCID: PMC9145563 DOI: 10.3390/ph15050508] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 04/18/2022] [Accepted: 04/20/2022] [Indexed: 02/05/2023] Open
Abstract
Therapeutic monoclonal antibodies (mAbs) have been a promising therapeutic approach for several diseases and a wide variety of mAbs are being evaluated in clinical trials. To accelerate clinical development and improve the probability of success, pharmacokinetics and pharmacodynamics (PKPD) in humans must be predicted before clinical trials can begin. Traditionally, empirical-approach-based PKPD prediction has been applied for a long time. Recently, modeling and simulation (M&S) methods have also become valuable for quantitatively predicting PKPD in humans. Although several models (e.g., the compartment model, Michaelis–Menten model, target-mediated drug disposition model, and physiologically based pharmacokinetic model) have been established and used to predict the PKPD of mAbs in humans, more complex mechanistic models, such as the quantitative systemics pharmacology model, have been recently developed. This review summarizes the recent advances and future direction of M&S-based approaches to the quantitative prediction of human PKPD for mAbs.
Collapse
Affiliation(s)
- Kenta Haraya
- Discovery Biologics Department, Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba 412-8513, Japan;
- Correspondence:
| | - Haruka Tsutsui
- Discovery Biologics Department, Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba 412-8513, Japan;
| | - Yasunori Komori
- Pharmaceutical Science Department, Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba 412-8513, Japan; (Y.K.); (T.T.)
| | - Tatsuhiko Tachibana
- Pharmaceutical Science Department, Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba 412-8513, Japan; (Y.K.); (T.T.)
| |
Collapse
|